# cabergoline

### notes
+ prescription under medical supervision

### therapeutic action
+ long-lasting lactation inhibitor

### indications
+ inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death

### presentation
+ 0.5 mg scored tablet

### dosage and duration
+ lactation inhibition  
    1 mg as a single dose on the first day post-partum
+ lactation suppression  
    0.25 mg every 12 hours for 2 days

### contra-indications, adverse effects, precautions
+ do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, and history of pulmonary, retroperitoneal or pericardial fibrosis.
+ may cause: hypotension, valvulopathy, dizziness, headache, nausea, drowsiness, allucinations.
+ do not combine with chlorpromazine, haloperidol, metoclopramide, promethazine (effect of cabergoline antagonised), methylergometrine (risk of vasoconstriction and hypertensive crisis), and macrolides (effect of cabergoline increased).
+ *pregnancy*: contra-indicated

### remarks
+ the use of cabergoline is not recommended to inhibit lactation in women who chose to not breastfeed: it is not justified to expose women to the adverse effects of cabergoline, lactation will stop spontaneously.
+ cabergoline is not included in the who list of essential medicines.
+ cabergoline is a dopamine agonist also used in the treatment of parkinson’s disease.
+ storage: below 25°c

